ClinicalTrials.gg
Enrolling by invitationNCT06854302CorMicA-PCIUpdated Nov 17, 2026

Angina After PCI: a Systems Medicine Study

An observational study in Angina (Stable) and Ischemic Heart Disease (IHD), sponsored by NHS National Waiting Times Centre Board. Enrolling by invitation at 4 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by NHS National Waiting Times Centre Board · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Angina, Stable with a site in United Kingdom — 8 open to participants now, 13 under way, none of them phase 3. Angina, Stable · United Kingdom.

Planned enrollment
13th of 21
600 · median 20,000
Started
2024
with 2 others
Observational
21 of 47
4 open now
Primary completion
2027-09
later than 7 of 12 live
Registered
43rd of 47
by date
Lead sponsor
4 of 47
NHS National Waiting Times Centre Board

Among the 47 studies in Angina, Stable with a site in United Kingdom, this one is the 13th largest by planned enrollment of the 21 observational ones that give a count, is one of 3 that started in 2024, is one of 21 observational ones, reaches primary completion later than 7 of the 12 other live ones, and was the 43rd registered.

Angina, Stable

344 studies on the registry are indexed under Angina, Stable; 56 are open to participants now.

Browse Angina, Stable studies →

Open to participants now

8 of the 47 studies in Angina, Stable with a site in United Kingdom are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 38 Angina, Stable studies recruiting now, 32 (84%) set no upper age limit and 2 (5%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Angina, Stable with a site in United Kingdom, or all of them as a file.
02

Study summary

Angina may persist or recur in patients treated by coronary angioplasty. The angioplasty involves a balloon treatment to open a blocked heart blood vessel and usually a stent (thin metal tube) is placed. Stents do not always improve symptoms and may make symptoms worse. Sometimes a drug-eluting-balloon is used instead of a stent.

This balloon coats the inside of the blood vessel to prevent re-narrowing. Research is needed to clarify the causes of ongoing angina and its impact on patients and the NHS, and to identify which patients will or will not benefit from a stent (hence avoiding over-treatment in the future).

We plan a 5-year UK-wide multicenter study involving up to 600 patients with angina undergoing coronary angioplasty (with or without a stent). They will initially have a heart MRI scan. We will assess what might influence the recurrence of angina in the year after the angioplasty procedure. We will measure small blood vessel function in the heart and the amount of plaque persisting after PCI.

Patients who report angina after coronary angioplasty usually have a second invasive angiogram. Instead, we will invite patients to have a heart MRI scan allowing us to also assess whether this scan might be more useful than a repeat angiogram in guiding clinical care. We will collaborate with life scientists, mathematicians, statisticians, and health economists to better understand causes and health economic implications of angina arising after coronary angioplasty procedures.

Read the detailed description

Background: Prior studies indicate that potentially one in three patients may experience angina within 12 months of undergoing percutaneous coronary intervention (PCI).

Hypothesis: 1) Diffuse coronary atherosclerosis and/or microvascular dysfunction impair myocardial blood flow (MBF) leading to angina post-PCI.

Design: A 5-year interdisciplinary program with 3 scientific work-packages (WPs): 1) Clinical, 2) Systems medicine, and 3) Health Economics.

WP1) Cohort study In 4 or more centers in the United Kingdom, 600 patients with angina will undergo stress/rest perfusion cardiovascular magnetic resonance (CMR) imaging with inline pixel-mapping of MBF (ml/min/g) and then coronary physiology measured during PCI. Patient reported outcome measures will be collected routinely during follow-up to 12 months.

Primary outcome: Adjudicated, residual angina (Seattle Angina Questionnaire Angina Frequency (SAQ-7-AF) score \<90).

Nested case-control study: stress perfusion CMR (MBF culprit artery territory, primary outcome) in approximately 200 patients reporting residual angina and 50 consecutive asymptomatic controls (all post-PCI). Clinically indicated coronary angiography including physiology tests (change from baseline measurement) and acetylcholine testing will be undertaken in approximately 120 patients.

WP2) Systems medicine (n=600) using biostatistics to identify multivariable baseline associates (clinical, coronary physiology, haemodynamics, circulating biomarkers (DNA, RNA, protein) of the SAQ-7-AF score (range 0 (Severe) - 100 (no angina)) post-PCI.

WP3) Health economics of NHS resource utilization and value of information (VoI) modelling to design stratified medicine trials.

Value: Identification of mechanisms to inform downstream diagnostic and therapeutic strategies for angina post-PCI.

03

Conditions studied

  • Angina (Stable)
  • Ischemic Heart Disease (IHD)

Keywords

  • Angina
  • Microvascular angina
  • Percutaneous coronary intervention
  • Systems medicine
  • Health economics
  • cohort study
  • coronary artery disease
  • Cardiovascular magnetic resonance imaging
  • Coronary physiology
  • Health-related quality of life
  • Clinical outcomes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with stable angina in whom stress perfusion CMR imaging is reasonable on clinical and/or research grounds and in whom invasive management is plausible or intended will be eligible to participate.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

BEFORE INVASIVE MANGEMENT

  1. Angina by SAQ-7 Angina Frequency Score \<90*
  2. Stress CMR imaging*

    DURING INVASIVE MANAGEMENT

  3. PCI (successful)
  4. Coronary physiology assessment post-PCI.

Exclusion criteria

Exclusion Criteria:

  1. Age \<=18 years
  2. Acute MI within 30 days
  3. Invasive management >90 days after stress CMR
  4. Inability to comply with the protocol
  5. Lack of written .
  6. Pregnancy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients receiving percutaneous coronary intervention

    The study population will include individuals with stable angina who undergo stress perfusion cardiovascular magnetic resonance (CMR) imaging before invasive management. Eligibility will be sequentially assessed. Informed consent will initially be based on angina occurring in patients in whom there is a reasonable expectation for invasive management. Stress CMR imaging should be undertaken on either clinical grounds or for research. Potentially, 700 patients will provide written informed consent. Finally, eligibility will be reassessed during invasive management and eligibility will be confirmed when percutaneous coronary intervention is completed. The population will be defined by individuals who fulfil the eligibility criteria. The target sample size is 600 patients with complete data post-PCI. This sample size is anticipated to lead to approximately 200 participants who will report angina consistent with an Seattle Angina Questionnaire Angina Frequency score \<90.

    Diagnostic Test: Cardiovascular magnetic resonance imaging · Diagnostic Test: Coronary physiology

Interventions

  • Diagnostic testCardiovascular magnetic resonance imaging

    Observational diagnostic tests will include adenosine-stress perfusion cardiovascular magnetic resonance imaging before undergoing percutaneous coronary intervention.

  • Diagnostic testCoronary physiology

    Invasive coronary function tests using a diagnostic guidewire (PressureWire-X, Abbott), thermodilution, intravenous or intracoronary infusion of adenosine and intracoronary infusions of acetylcholine.

06

What researchers measure

Primary outcomes

  1. Residual angina after percutaneous coronary intervention.

    Residual angina post-PCI, defined as adjudicated, angina (Seattle Angina Questionnaire Angina Frequency (SAQ-7-AF) score \<90) occurring within one year of percutaneous coronary intervention.

    Time frame: From enrolment to 12 months

Secondary outcomes

  1. Angina

    Angina severity will be assessed using the Seattle Angina Questionnaire Summary Score.

    Time frame: From enrolment to 12 months

  2. Myocardial perfusion reserve

    Myocardial perfusion reserve (MPR) within the distribution of the target coronary artery/ies revealed by cardiovascular magnetic resonance (CMR) imaging.

    Time frame: From enrolment to 12 months

  3. Fractional flow reserve post-percutaneous coronary intervention

    Fractional flow reserve after percutaneous coronary intervention, reflecting the success of the procedure.

    Time frame: 24 hours

  4. Coronary flow reserve after percutaneous coronary intervention

    Coronary flow reserve (CFR) post-PCI. Coronary flow reserve takes account of adenosine-mediated vasodilatation of the coronary artery and microcirculation. A CFR \<2.0 is abnormal, a CFR 2.0-\<2.5 is impaired and a CFR\>2.5 is normal.

    Time frame: 24 hours

  5. Index of microvascular resistance after percutaneous coronary intervention

    Index of microvascular resistance (IMR) post-PCI. IMR reflects adenosine-mediated minimal microvascular resistance. An IMR \>=25 is abnormal.

    Time frame: 24 hours

  6. Microvascular dysfunction after percutaneous coronary intervention

    Microvascular dysfunction is defined as a CFR\<2.5 and/or an IMR\>=25 post-PCI.

    Time frame: 24 hours

  7. Health-related quality of life

    Health-related quality of life will be assessed using the EuroQol-5D 5 Level (5L) questionnaire. EQ-5D-5L is a health status questionnaire that measures five dimensions of health: mobility, self-care, usual activities, pain/discomfort and anxiety/depression

    Time frame: From enrolment to 12 months

  8. Physical function

    The Duke Activity Status Index (DASI) is a self-administered questionnaire with a 12-item scale that estimates physical functional capacity, cardiorespiratory function and metabolic equivalents (METs).

    Time frame: From enrolment to 12 months

  9. Illness perception

    Brief Illness Perception Questionnaire (BIPQ) is a nine-item scale that measures the cognitive and emotional representations of illness.

    Time frame: From enrolment to 12 months

  10. Anxiety and depression

    Patient Health Questionnaire-4 (PHQ-4) is a self-reported questionnaire to assess for anxiety and depression over the last 2 weeks. Scores are rated as normal (0-2), mild (3-5), moderate (6-8), and severe (9-12). Total score ≥3 for first 2 questions suggests anxiety.

    Time frame: From enrolment to 12 months

  11. Productivity loss

    The Institute for Medical Technology Assessment (iMTA) Productivity Cost Questionnaire (iPCQ) is a generic tool to measure productivity losses.

    Time frame: From enrolment to 12 months

  12. Fraility

    The Rockwood Clinical Frailty Scale (CFS) is a tool to summarize the overall level of fitness or frailty of an older individual.

    Time frame: From enrolment to 12 months

  13. Serious adverse events

    Serious adverse events (SAE) post-enrolment will be assessed using electronic health records without the need for participant contact. The SAE of interest are pre-specified in the protocol. Where e-health records are not an option, then an annual contact with the participant should be undertaken to assess for SAE. The final visit is defined as when the last participant has completed 12 months follow-up. The minimum duration of follow-up will be 12 months and the maximum duration of follow-up is anticipated to be up to 48 months. Longer term follow-up to 20 years will be undertaken using electronic health record linkage.

    Time frame: From enrolment to 12 months

  14. Low density lipoprotein

    Abnormal lipid metabolism, and hyperlipidemia, mediate atherogenesis. The circulating concentrations of low density lipoprotein, a proatherogenic lipid, will be assessed.

    Time frame: From enrolment to 12 months

Other outcomes

  1. Inflammation

    Systemic inflammation may underlie the pathogenesis of resistant angina. Systemic inflammation will be assessed by measurement of the circulating concentration of C-reactive protein.

    Time frame: From enrolment to 12 months

  2. Glycemic status

    Glycemic status may underlie the pathogenesis of resistant angina. Cardiometabolic status will be assessed by measurement of the circulating concentration of glycated hemoglobin (HbA1c), a metabolic biomarker.

    Time frame: From enrolment to 12 months

  3. Myocardial injury

    The circulating concentration of troponin, measured using a high sensitivity assay, reflects ischemic myocardial injury or infarction.

    Time frame: From enrolment to 12 months

  4. Lipoprotein(a)

    Abnormal lipid metabolism, and hyperlipidemia, mediate atherogenesis. The circulating concentrations of lipoprotein(a), a proatherogenic lipid, will be assessed.

    Time frame: From enrolment to 12 months

  5. Microvascular dysfunction (acetylcholine test population)

    Microvascular dysfunction is defined as a composite outcome including the occurence of CFR\<2.5 and/or an IMR\>=25 and/or microvascular spasm (acetylcholine). Since acetylcholine-mediated microvascular spasm may reflect microvascular dysfunction, in the subpopulation also undergoing acetylcholine coronary reactivity testing, the microvascular dysfunction outcome measure will include the response to acetylcholine (yes/no), and CFR\<2.5 and/or IMR\>=25.

    Time frame: 24 hours

  6. Microvascular blood flow

    The ratio of stress subendocardial myocardial blood flow / stress subepicardial myocardial blood flow. Myocardial blood flow is estimated as ml/min/g myocardial tissue on the American Heart Association model of myocardial segments.

    Time frame: From enrolment to 12 months

  7. Impaired myocardial blood flow

    Extent of impaired hyperemic myocardial blood flow (MBF, ml/min/g), defined as the ordinal number of segments with impaired peak hyperemic myocardial blood flow according to consensus-based, reference thresholds (PMID: 30772231). A regional perfusion defect is defined as myocardial blood flow \<2.0 ml/min/g in one or more segments. If the perfusion defect is global (rather than regional) and suspected as being due to microvascular disease, then the MBF threshold is \<2.25 ml/min/g.

    Time frame: From enrolment to 12 months

  8. Coronary vasomotor dysfunction in response to intracoronary infusion of acetylcholine

    Coronary vasomotor dysfunction in response to intracoronary infusion of acetylcholine. Vasomotor dysfunction is defined as coronary artery spasm and/or microvascular spasm according to contemporary diagnostic criteria (PMID: 39210710).

    Time frame: From enrolment to 12 months

  9. Myocardial blood flow (hyperaemic, global)

    Hyperemic myocardial blood flow (MBF, ml/min/g) in all segments.

    Time frame: From enrolment to 12 months

07

Study locations

4 sites
08

References and documents

Publications

  • Crea F, Bairey Merz CN, Beltrame JF, Berry C, Camici PG, Kaski JC, Ong P, Pepine CJ, Sechtem U, Shimokawa H. Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization. Eur Heart J. 2019 Aug 1;40(29):2455-2462. doi: 10.1093/eurheartj/ehy857. PubMed 30608528 ↗

Individual participant data

Plan to share: Yes — IPD will be shared with bone fide research collaborators upon reasonable request with the agreement of the sponsor and chief investigator

Supporting information: Study protocol

Time frame: After the completion of the study

Access criteria: Bone fide research collaborators by contacting the chief investigator.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2027, 36 months after the start.

Of 52 observational studies under Angina, Stable, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 79. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2024
First posted
Mar 3, 2025
StartActual
Sep 17, 2024
Primary completionEst.
Sep 2027
CompletionEst.
Oct 1, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06854302
Lead sponsor
NHS National Waiting Times Centre Board
Collaborators
Robertson Centre for Biostatistics - University of Glasgow, British Heart Foundation, Abbott Medical Devices, CoreAalst BV, National Heart, Lung, and Blood Institute (NHLBI)
Responsible party
Colin Berry (Professor of Cardiology and Imaging, NHS National Waiting Times Centre Board) — Principal investigator
First posted
Mar 3, 2025
Start date
Sep 17, 2024
Primary completion
Sep 2027 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Colin Berry, BSc MBChB PhD
principal investigator · University of Glasgow

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion